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Comment On: Protective Role of Recombinant Human Erythropoietin in Kidney 
and Lung Injury Following Renal Bilateral Ischemia‑reperfusion in Rat Model
Mohammad‑Reza Ardalan, Hamid Nasri1, Mahmoud Rafieian‑Kopaei2
DEAR EDITOR,
We read with great interest the nice published an 
article by Moeini, et al. in the esteemed “International 
Journal Preventive Medicine” entitled: Protective 
role of  recombinant human erythropoietin (EPO) 
in kidney and lung injury following renal bilateral 
ischemia/reperfusion (I/R) in the rat model. 
Article has some interesting points need more 
explain. In this study Moeini et al. aimed to study 
the role of  EPO on kidney function makers and 
tissue damage; and lung endothelial permeability 
and lung water content in bilateral renal I/R injury 
model in rats.[1] In the study on male Wistar rats, 
which were divided into three groups of  sham, 
I/R and I/R treated with EPO (I/R + EPO) 
groups. The I/R and I/R + EPO groups were 
assigned to bilateral renal I/R injury, while the 
I/R + EPO group received EPO (500 IU/kg, i.p.) 
2 h before ischemia surgery and the same dose was 
continued once a day for 3 days after ischemia. In 
the study on male Wistar rats, which were divided 
into three groups of  sham, I/R and I/R treated 
with EPO (I/R + EPO) groups. The I/R and 
I/R + EPO groups were assigned to bilateral renal 
I/R injury, while the I/R + EPO group received 
EPO (500 IU/kg, i.p.) 2 h before ischemia surgery 
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and the same dose was continued once a day 
for 3 days after ischemia. They measured serum 
blood urea nitrogen (BUN) and creatinine (Cr) 
levels. They also assessed kidney tissue damage 
score. They found, EPO administration decreased 
levels of  BUN and Cr significantly. Furthermore 
administration of  EPO increased the renal level of  
nitrite.[1] They concluded that, EPO protected the 
kidney against I/R injury. In a study of  40 male 
Wistar rats, conducted to test the protective effect 
of  EPO on tubular cells, we observed that EPO 
was capable to prevent the increase in serum Cr 
and BUN levels against gentamicin renal toxicity. 
Moreover, co‑administration of  gentamicin and 
EPO efficiently reduced the kidney tissue injury 
induced by gentamicin, compared with the control 
group.[2] Our investigation revealed the kidney 
protective effect of  EPO, when the drug was 
administered in combination with gentamicin.[3‑6] 
Nevertheless, the protective properties of  EPO 
were evident even when the drug was given after 
induction of  renal tubular injury by gentamicin 
and it was still effective after tissue damage.[2‑6] This 
indicates that EPO may have a curative impact, 
along with its preventive properties.[5‑9] Hence, 
EPO is a promising renal protective medication 
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that can prevent, ameliorate, or attenuate tubular 
injury induced by gentamicin or other injurious 
insults such as I/R.[7‑10] Previous investigators also 
showed the efficacy of  EPO on kidney allograft 
survival too.[11] Recently much attentions has 
been directed toward renoprotective property 
of  EPO beyond stimulating erythropoiesis.[12‑16] 
In a preclinical study on 6 weeks old male rats, 
which treated with cyclosporine, Abe et al. found 
that carbamylated EPO suppressed macrophage 
infiltration, phenotypic alteration of  interstitial 
myofibroblasts and interstitial fibrosis in the 
cyclosporine nephropathy model. They also 
observed that, carbamylated EPO administration 
decreased transforming growth factor‑β1 messenger 
ribonucleic acid levels in cyclosporine – Treated 
kidneys. In the present study, tubular apoptosis was 
persistently stimulated after central sleep apnea 
treatment, while carbamylated EPO significantly 
inhibited tubular apoptosis. They concluded 
carbamylated EPO administration reduced 
cyclosporine – Induced tubulointerstitial injury 
in two ways by protection of  tubular epithelial 
cells from apoptosis and inhibition of  interstitial 
fibrosis.[17] Recently also some investigators 
envisage to administer the EPO therapy in chronic 
kidney disease prior to anemia, benefiting its 
kidney protective efficacy of  EPO in chronic 
kidney disease too.[18] Indeed it may be reasonable 
that we start EPO prior to erythropoiesis. Hence, 
to better understand the renoprotective properties 
of  EPO, more experimental or clinical studies are 
suggested.
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